Abstract
Background: Opioid dependence is a major health concern across the world and does also occur in adolescents. While opioid substitution treatment (OST) has been thoroughly evaluated in adult populations, very few studies have examined its use in adolescents. There are concerns that OST is underutilised in adolescents with heroin dependence. We sought to measure changes in drug use among adolescents receiving OST and also to examine treatment attrition during the first 12 months of this treatment. Methods: We included all heroin dependent patients aged under 18.5 years commencing OST at one outpatient multidisciplinary adolescent addiction treatment service in Dublin, Ireland. Psycho-social needs were also addressed during treatment. Drug use was monitored by twice weekly urine drugs screens (UDS). Change in the proportion of UDS negative for heroin was examined using the Wilcoxon signed rank test. Attrition was explored via a Cox Regression multivariate analysis. Results: OST was commenced by 120 patients (51% female and mean age 17.3 years). Among the 39 patients who persisted with OST until month 12, heroin abstinence was 21% (95% confidence interval [CI]=9-36%) at month three and it was 46% (95% CI=30-63%) at month 12. Heroin use declined significantly from baseline to month three (p<0.001) and from month three to month 12 (p=0.01). Use of other drugs did not change significantly. People using cocaine during month 12 were more likely to be also using heroin (p=0.02). Unplanned exit occurred in 25% patients by 120 days. The independent predictors of attrition were having children, single parent family of origin, not being in an intimate relationship with another heroin user and evidence of cocaine use just before treatment entry. Conclusions: We found that heroin dependent adolescent patients achieved significant reductions in heroin use within three months of starting OST and this improved further after a year of treatment, about half being heroin abstinent at that stage. Patient drop out from treatment remains a challenge, as it is in adults. Cocaine use before and during treatment may be a negative prognostic factor.
Original language | English |
---|---|
Article number | 151 |
Journal | BMC Pediatrics |
Volume | 18 |
Issue number | 1 |
DOIs | |
Publication status | Published - 4 May 2018 |
Bibliographical note
Funding Information:BPS has received lecture fees from Pfizer, Shire and Eli Lilly. BPS was a co-PI in a RCT examining buprenorphine induction which recruited patients from the NDTC. That RCT was funded by Schering-Plough (now Merck), a distributor of buprenorphine worldwide. BPS was the lead clinician at the treatment service (the YPP) where this study was conducted. BPS has no other competing interest. Neither KE nor WC has any competing interest.
Publisher Copyright:
© 2018 The Author(s).
Keywords
- Adolescents
- Buprenorphine treatment
- Heroin dependence
- Methadone treatment
- Treatment adherence
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health